China Conditionally Approves MSD's Molnupiravir for COVID-19 Treatment

by Grace Wang Jan 05, 2023

On Dec. 29, 2022, China National Medical Products Administration (NMPA) conditionally approved Merck Sharp & Dohme (MSD)’s Molnupiravir Capsules (brand name: Lagevrio) for COVID-19 treatment. 

The antiviral small-molecule drug is approved for treating patients who have mild-to-moderate COVID-19 infections and high risks to develop into severe conditions. The risks can be advanced age, obesity or overweightness, chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease (COPD), active cancer, etc. 

MSD has authorized Sinopharm Group with the exclusive right to import and sell Lagevrio in the mainland Chinese market.

Lagevrio’s price in China has not been revealed. In the US, one course costs 700 USD (circa 4,818 yuan).

By Jan. 31, 2023, China NMPA has approved six COVID-19 treatments:

Drug

Administra-tion Route

Marketing Authorization Holder

Approval Date

Price for One Course

Within Basic Insurance

Without Basic Insurance

Amubarvimab/

Romlusevimab Combination Therapy (BRII-196/BRII-198)

Injection

Brii Biosciences

Dec. 8, 2021

Brii Biosciences revealed the price scope: 10,000 yuan

/

Nirmatrelvir Tablets and Ritonavir Tablets (Paxlovid)

Oral

Pfizer

Feb 11, 2022

1,890 yuan until Mar. 31, 2023

2,300 yuan

Azvudine Tablets

Oral

Genuine Biotech

July 25, 2022

350 yuan

540 yuan

Molnupiravir Capsules (Lagevrio)

Oral

MSD

Dec. 29, 2022

1,500 yuan

/

Simnotrelvir Tablets / Ritonavir Tablets (Xian Nuo Xin)

Oral

Simcere

Jan. 29, 2023

750 yuan

/

VV116

Oral

Shanghai Vinnerna Biosciences (joint venture of Junshi Biosciences and Suzhou Wangshan Wangshui Biomedicine)

Jan. 29, 2023

Not revealed

Not revealed

Updated on Jan. 31, 2023

Related:

-       China's First Homegrown COVID-19 Pill, Azvudine, is Priced at 270 Yuan Per Bottle

-       China Approves Pfizer's Paxlovid, Encouraging COVID-19 Drug Development

Grace Wang
ChemLinked Regulatory Analyst / Editor
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2023 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com